A new typhoid conjugate vaccine (TCV) offers:

- Longer-lasting protection compared to other available typhoid vaccines.
- Fewer required doses.
- Suitability for children 6 months of age and older.
- Opportunity for inclusion in routine childhood immunization programs.

Typbar-TCV:

- Is manufactured by Bharat Biotech International Limited.
- Can be administered to adults, children, and infants 6 months of age and older.
- Offers long-lasting protection with a single 0.5mL dose injected intramuscularly.
- Presents as ready-to-use liquid in a 5-dose vial with 36-month shelf life when stored at 2-8°C.

The World Health Organization encourages:

- TCV introduction prioritized in countries with highest typhoid burden or high burden of drug-resistant typhoid.
- Programmatic administration at same time as other vaccine visits at 9 months of age or in second year of life.
- Catch-up vaccination campaigns up to 15 years of age.
- Use in response to confirmed outbreaks of typhoid.

Expanded use of TCVs can:

- Reduce the need for antibiotics.
- Slow further emergence of drug-resistant typhoid.
- Decrease prevalence of disease.
- Save lives.
Gavi, the Vaccine Alliance timeline: Application to introduction

Countries should allow 15-18 months between application preparation and implementation, assuming both routine and campaign introduction.